News zum Sektor Gesundheit aus Frankreich

 

Could it be a biotech giant in the making?...

The mean of analysts' price targets for Inventiva (IVA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....

Von Colin Kellaher DOW JONES--Der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur hat die Zulassung des entzündungshemmenden Blockbuster-Medikaments Dupixent von Regeneron ......

PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) Friday said the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has issued a positive ......

Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment...

PARIS (dpa-AFX) - Sanofi SA (SNY) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Acoziborole Winthrop for the treat......

PARIS, FRANCE, 27 FEBRUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional marketing authorization of Ojemda® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (pLGG) harbouring a BRAF fusion or rearrangement or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.i...

FOP is an ultra-rare condition, impacting fewer than 1,000 people worldwide. The collaboration involves containment, specialised handling, and sustained supply of this highly potent molecule. The agreement includes The post Quotient and Ipsen extend partnership for ultra-rare disease therapy appeared first on Pharmaceutical Business review....

A new therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens for sleeping sickness....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

PARIS (dpa-AFX) - BioMerieux SA (EYWN.MU) reported earnings for full year that Drops, from the same period last yearThe company's bottom line totaled EUR397.5 million, or EUR3.34 per share. This c......

OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 26, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its fourth quarter 2025 revenues and cash position results1 and provides a corporate update....

ABIVAX: Nombre d'actions composant le capital social et nombre total de droits de vote au 31.01.26....

PHILADELPHIA , Feb. 26, 2026 /PRNewswire/ -- Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a......

LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables......

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF) has filed its 2025 Annual Report and its 2025 Environmental, Social and Governance Report for the year ended 31 December 2025 with the electronic database of the Luxembourg Stock Exchange (www.bourse.lu) on 26 February 2026. They are available on the Eurofins website, www.eurofins.com, under the heading Investors / Results and Presentations. The Annual Report contains: The Management Report The Remuneration Report The Corporate Governance Report The Audited Annual Financial Statements Notes to Editors: For more information, please visit www.eurofins.com. About Eurofins – the global leader in bio-analysis Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leade...

Ramsay Health Care posted half-year earnings growth, higher dividends, and announced a potential Ramsay Santé share distribution. The post Ramsay Health Care posts 1H FY26 earnings; lifts dividend appeared first on The Motley Fool Australia....

PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March:...

        PRESS RELEASE...